Phathom Pharmaceuticals, Inc.
PHATNASDAQHealthcare● Active
$9.92
$-0.22(-2.12%)
Market Cap$790779748
P/E Ratio—
52W High$18.31
52W Low$4.471
Phathom Pharmaceuticals, Inc. (PHAT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PHAT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.18B | $0.06B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.15B | $0.05B | $0.00B | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | 87.09% | 85.57% | 75.51% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.03B | $0.05B | $0.07B | $0.07B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.31B | $0.32B | $0.17B | $0.17B | $0.13B |
| Operating Income | ($0.16B) | ($0.28B) | ($0.17B) | ($0.17B) | ($0.14B) |
| Operating Margin %(computed) | -91.36% | -502.18% | — | — | — |
| Interest Income | $0.01B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.07B | $0.07B | $0.04B | $0.03B | $0.01B |
| Income Before Tax | ($0.22B) | ($0.33B) | ($0.20B) | ($0.20B) | ($0.14B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.22B) | ($0.33B) | ($0.20B) | ($0.20B) | ($0.14B) |
| Net Margin %(computed) | -126.35% | -605.09% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.03 | $-5.29 | $-3.93 | $-5.70 | $-4.00 |
| Wtd Avg Shares | 0.07B | 0.06B | 0.05B | 0.04B | 0.04B |
| EBITDA | ($0.16B) | ($0.26B) | ($0.16B) | ($0.17B) | ($0.14B) |
| EBITDA Margin %(computed) | -91.00% | -473.33% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Phathom Pharmaceuticals, Inc. data
About Phathom Pharmaceuticals, Inc. (PHAT) Income Statement
Phathom Pharmaceuticals, Inc. (PHAT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PHAT reported revenue of $0.18B, gross profit of $0.15B (gross margin 87.09%), and net income of ($0.22B) — a net profit margin of -126.35%.
Frequently asked questions
PHAT · 4 questionsPhathom Pharmaceuticals, Inc. (PHAT) reported revenue of $0.18B for 2025, up 216.9% year-over-year.
PHAT revenuePHAT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08